| Joy Elaine Batt, NP | |
|
1000 Pole Creek Xing, Sidney, NE 69162-2901 | |
| (308) 254-5825 | |
| (308) 254-7268 |
| Full Name | Joy Elaine Batt |
|---|---|
| Gender | Female |
| Speciality | Family Medicine - Adult Medicine |
| Location | 1000 Pole Creek Xing, Sidney, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558991687 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QA0505X | Family Medicine - Adult Medicine | 114160 (Nebraska) | Primary |
| 207QA0505X | Family Medicine - Adult Medicine | APN.0995016-NP (Colorado) | Secondary |
| Entity Name | Cheyenne County Hospital Association Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487736963 PECOS PAC ID: 1658345657 Enrollment ID: O20050301000906 |
News Archive
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
Developed countries "gave more aid to poorer countries than ever before in 2010, despite facing big budget gaps and rising debt levels," according to data released on Wednesday by the Organization for Economic Cooperation and Development (OECD), Dow Jones Newswires/Wall Street Journal reports.
The future of regenerative medicine lies in harnessing the potential of the human body to renew and repair itself. Now, scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a new genetic engineering technique that promises safer stem cell therapy for cancer patients. Using an insect virus, the team of researchers successfully inserted a therapeutic gene into a safe site in the DNA of human embryonic stem cells without compromising the functionality of the engineered cells.
Catalyst Health Solutions, Inc. today announced it has completed its acquisition of Walgreens' pharmacy benefit management (PBM) subsidiary, Walgreens Health Initiatives, Inc. (WHI). Catalyst funded the transaction with a combination of cash on hand and amounts available under its credit facility.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joy Elaine Batt, NP 215 S 4th St, Sterling, CO 80751-4233 Ph: (970) 522-4247 | Joy Elaine Batt, NP 1000 Pole Creek Xing, Sidney, NE 69162-2901 Ph: (308) 254-5825 |
News Archive
GlaxoSmithKline and XenoPort, Inc. (Nasdaq: XNPT) today announced that the U.S. Food and Drug Administration (FDA) has extended the original Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) for GSK1838262/XP13512 (gabapentin enacarbil) to February 9, 2010. The original PDUFA date for this NDA review was November 9, 2009.
Developed countries "gave more aid to poorer countries than ever before in 2010, despite facing big budget gaps and rising debt levels," according to data released on Wednesday by the Organization for Economic Cooperation and Development (OECD), Dow Jones Newswires/Wall Street Journal reports.
The future of regenerative medicine lies in harnessing the potential of the human body to renew and repair itself. Now, scientists at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a new genetic engineering technique that promises safer stem cell therapy for cancer patients. Using an insect virus, the team of researchers successfully inserted a therapeutic gene into a safe site in the DNA of human embryonic stem cells without compromising the functionality of the engineered cells.
Catalyst Health Solutions, Inc. today announced it has completed its acquisition of Walgreens' pharmacy benefit management (PBM) subsidiary, Walgreens Health Initiatives, Inc. (WHI). Catalyst funded the transaction with a combination of cash on hand and amounts available under its credit facility.
› Verified 1 days ago
James Kenneth Popovich, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Pole Creek Xing Ste 1, Sidney, NE 69162 Phone: 308-254-5554 | |
Sara M Sholar, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Pole Creek Xing, Sidney, NE 69162 Phone: 308-254-5825 | |
Dr. Emily B Crockett, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1000 Pole Creek Xing Ste 1, Sidney, NE 69162 Phone: 308-254-5544 Fax: 308-254-0396 | |
Dr. Calvin W Cutright, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1625 Dorwart Dr, Sidney, NE 69162 Phone: 308-254-5544 Fax: 308-254-2672 | |
Dr. Clinton B Dorwart, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1625 Dorwart Dr, Sidney, NE 69162 Phone: 308-254-5544 Fax: 308-254-2672 | |
Mrs. Rebecca L Allard, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Pole Creek Xing Ste 1, Sidney, NE 69162 Phone: 308-254-5544 Fax: 308-254-7258 |